Dr. Robert Berman first discovered the antidepressant effects of ketamine in humans alongside Dr John Krystal in 1990s at Yale. For over 20 years he has worked within the industry, first at Pfizer and then Bristol-Myers Squibb in clinical development roles, including leading the program for aripiprazole in depression, for which he developed novel clinical trial design that achieved three out of three highly statistically significant trials. In 2013, Rob co-founded Biohaven Pharmaceuticals (NYSE:BHVN) and was Chief Medical Officer until 2019.

Dr. Alex Kwan is a neuroscientist whose work is focused on the neurobiology of antidepressants. He is known for using sophisticated optical imaging methods to show how drugs such as ketamine and psilocybin modify the structure and function of brain circuitry. His research has been published in top peer-reviewed journals including Nature Neuroscience, Neuron, and Biological Psychiatry. He has a Ph.D. in Applied Physics from Cornell University and is currently an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University.

Dr. Gerard Sanacora is the George D. Gross and Esther S. Gross Professor of Psychiatry at the Yale University School of Medicine, Director of the Yale Depression Research Program, and Co-Director of the Interventional Psychiatry Program at Yale-New Haven Hospital. For the past 25 years his research has focused using both preclinical and clinical studies in attempts to expand our understanding of the pathophysiology of mood disorders and to use this information in developing new approaches in treating mood and other neuropsychiatric disorders.